Immune Thrombocytopenic Purpura (ITP)

01Pathophysiology

ITP is an autoimmune disorder in which the body produces IgG autoantibodies against platelet surface glycoproteins, most commonly GPIIb/IIIa and GPIb/IX. These opsonized platelets are then recognized and destroyed by splenic macrophages through Fc receptor-mediated phagocytosis in the reticuloendothelial system, predominantly within the spleen. This accelerated peripheral destruction is the primary mechanism of thrombocytopenia.

In addition to peripheral destruction, there is a component of impaired platelet production. The same autoantibodies can bind to megakaryocyte precursors in the bone marrow, suppressing thrombopoiesis. This dual mechanism (increased destruction plus decreased production) explains why platelet counts can drop to dangerously low levels.

The reason the patient presents with mucocutaneous bleeding (petechiae, purpura, epistaxis) rather than deep tissue or joint bleeding is directly tied to the role of platelets. Platelets are responsible for primary hemostasis, which is the formation of the initial platelet plug at sites of endothelial injury. When platelet counts fall, small vessel integrity is compromised, leading to bleeding in the skin and mucous membranes. This is in contrast to coagulation factor deficiencies (such as hemophilia), where secondary hemostasis is impaired and patients bleed into joints and deep tissues.

A critical concept for exam purposes: the bone marrow in ITP shows normal to increased megakaryocytes. The marrow is attempting to compensate for the peripheral destruction. This finding, if a bone marrow biopsy is performed, helps rule out marrow failure states (aplastic anemia, leukemia) where megakaryocytes would be decreased or replaced by abnormal cells.

In children, the disease is frequently triggered by a preceding viral infection (typically 1 to 4 weeks before onset), which is thought to cause molecular mimicry or immune complex formation that cross-reacts with platelet antigens. In adults, the disease tends to follow a more chronic, insidious course without a clear viral trigger and is more commonly associated with underlying autoimmune conditions.

02Classification and Clinical Manifestation

By Duration

By Etiology

By Severity

Pediatric vs. Adult Presentation

03Diagnostic Workup

ITP is fundamentally a diagnosis of exclusion. There is no single confirmatory test. The diagnostic process centers on demonstrating isolated thrombocytopenia while systematically ruling out other causes of low platelet counts.

The best initial test is the CBC with peripheral smear. The hallmark finding is isolated thrombocytopenia with an otherwise normal blood count. The peripheral smear is examined carefully: platelets that are present appear large and immature (reflecting the marrow's compensatory effort to release young platelets), and there must be no schistocytes (which would suggest microangiopathic hemolytic anemia such as TTP or HUS) and no blasts (which would suggest leukemia).

Coagulation studies (PT and aPTT) are ordered to confirm that the clotting cascade is intact. In ITP, these are normal because the problem is in primary hemostasis (platelet plug formation), not in secondary hemostasis (fibrin clot formation).

HIV and HCV testing are recommended for all adults because these infections can cause secondary ITP, and treatment of the underlying infection may resolve the thrombocytopenia. H. pylori testing is also recommended in adults; several studies have shown that eradication of H. pylori leads to sustained improvement in platelet counts in a subset of patients.

A Direct Antiglobulin Test (Coombs test) should be performed, particularly if there is any suggestion of concurrent anemia. A positive DAT in the setting of ITP and hemolytic anemia points to Evans syndrome (autoimmune hemolytic anemia + ITP), which has a different prognosis and treatment approach.

Bone marrow biopsy is not routinely required in typical ITP presentations. It is reserved for atypical scenarios: patients over age 60 (to rule out myelodysplastic syndrome), those with abnormalities in other cell lines, those who fail to respond to initial therapy, or when there is clinical suspicion for an infiltrative marrow process. When performed, the marrow in ITP shows normal to increased megakaryocytes with otherwise normal cellularity.

A common exam trap: antiplatelet antibody testing is not useful for diagnosis. Despite being an antibody-mediated disease, the available assays for antiplatelet antibodies have poor sensitivity (50 to 65%) and are not standardized. A negative result does not exclude ITP, and a positive result does not confirm it. Exam vignettes may include this as a distractor answer choice.

04Management and Treatment

Observation. Not every patient with ITP requires treatment. The threshold for initiating pharmacotherapy is generally a platelet count below 30,000/mcL or the presence of clinically significant bleeding regardless of count. In children, where spontaneous remission occurs in approximately 80% of cases within 6 months, observation with close follow-up is often the appropriate initial strategy. In adults, the decision to treat is guided by the bleeding risk, platelet count, and patient lifestyle/comorbidities.

First-line pharmacotherapy: Corticosteroids. When treatment is indicated, corticosteroids are the standard first-line therapy. Two regimens are commonly used. Dexamethasone 40 mg orally daily for 4 consecutive days (repeated in cycles if needed) has become the preferred regimen due to its rapid onset and shorter treatment duration. Alternatively, prednisone at 1 mg/kg/day for 2 to 4 weeks followed by a gradual taper is also effective. Steroids work by reducing autoantibody production and impairing Fc receptor-mediated phagocytosis. Response is typically seen within 1 to 2 weeks. Steroids should not be continued indefinitely at high doses due to side effects (hyperglycemia, osteoporosis, immunosuppression, adrenal suppression).

IVIG for rapid response. When a rapid increase in platelet count is needed (e.g., before a surgical procedure, in the setting of significant bleeding, or when platelets are critically low), IVIG at 1 g/kg IV for 1 to 2 days is administered. IVIG works by saturating the Fc receptors on splenic macrophages, thereby blocking the phagocytosis of opsonized platelets. Platelet counts typically rise within 24 to 48 hours, but the effect is temporary (lasting 2 to 4 weeks). IVIG is not a long-term solution; it is a bridge therapy.

Anti-D immunoglobulin (WinRho). This is an alternative to IVIG for rapid platelet elevation, but it can only be used in patients who are Rh-positive and have not undergone splenectomy. It works by coating Rh-positive red blood cells, which then compete with opsonized platelets for Fc receptor binding on splenic macrophages, effectively "distracting" the spleen. A notable adverse effect is hemolysis, and patients must be monitored for a drop in hemoglobin.

Emergency management. In the setting of life-threatening hemorrhage (intracranial hemorrhage, severe GI bleed), the approach is aggressive and multi-modal: platelet transfusion (even though platelets will be destroyed, they provide transient hemostatic benefit), high-dose IV methylprednisolone (1 g IV daily for 3 days), IVIG, and potentially aminocaproic acid (an antifibrinolytic) to stabilize clots. The key exam point: platelet transfusions are NOT absolutely contraindicated in ITP. In a life-threatening emergency, they should be given.

Splenectomy for chronic refractory ITP. For patients with chronic ITP (> 12 months) who fail medical therapy, splenectomy is the most established second-line treatment. It removes the primary site of both antibody production and platelet destruction. The durable response rate is approximately 65 to 70%. Pre-splenectomy vaccination against encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae type b, Neisseria meningitidis) is mandatory, ideally given at least 2 weeks before surgery.

TPO receptor agonists for chronic ITP. Thrombopoietin receptor agonists are an important treatment option for patients who are refractory to or ineligible for splenectomy. Eltrombopag (50 mg PO daily, adjusted based on response) and Romiplostim (1 to 10 mcg/kg SC weekly) stimulate megakaryocyte proliferation and differentiation in the bone marrow, thereby increasing platelet production to compensate for ongoing destruction. They do not address the underlying autoimmune mechanism but bypass it by boosting output. Monitoring for hepatotoxicity (eltrombopag) and bone marrow reticulin fibrosis (romiplostim) is necessary during long-term use.

Rituximab (anti-CD20 monoclonal antibody, 375 mg/m² IV weekly for 4 doses) is used off-label for chronic refractory ITP. It depletes B lymphocytes and thus reduces autoantibody production. Response rates are approximately 40 to 60%, but relapse is common.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common way students get ITP questions wrong is by ordering a bone marrow biopsy as the next best step. In a young, otherwise healthy patient with isolated thrombocytopenia, a normal peripheral smear, and no other abnormal findings, the answer is almost never bone marrow biopsy. ITP is a clinical and laboratory diagnosis of exclusion. A bone marrow biopsy is reserved for atypical cases (older patients, abnormal WBC or hemoglobin, failure to respond to treatment). When the vignette describes a well-appearing child with petechiae after a viral illness and the only lab abnormality is low platelets, the answer is either observation (if no significant bleeding and platelets > 30,000) or corticosteroids (if treatment is needed).

Another frequent trap involves platelet transfusion. Students often select "do not transfuse platelets" because they remember that platelets are being destroyed. While it is true that platelet transfusions provide only transient benefit in ITP, they are not contraindicated in emergencies. If the vignette describes a patient with active, life-threatening hemorrhage (intracranial bleed, massive GI bleeding), the correct answer includes platelet transfusion alongside IVIG and high-dose steroids.

Students also confuse ITP with TTP. The discriminating feature is the peripheral blood smear. If schistocytes are present, it is not ITP. ITP has large but morphologically normal platelets and no fragmented red blood cells. If the vignette mentions fever, neurologic changes, renal dysfunction, or hemolysis, the answer shifts to TTP or HUS.

Finally, remember that antiplatelet antibody testing is not the answer for confirming ITP. Despite the disease being antibody-mediated, the test is neither sensitive nor reliable enough for clinical use. The diagnosis rests on the clinical picture and the exclusion of other causes. The core competency being tested with ITP questions is the ability to recognize an isolated platelet problem in a well-appearing patient, resist the urge to over-investigate, and select the appropriate level of intervention based on platelet count and bleeding severity.